What's on this Page
What is Prazepam
NOTE: This drug is discontinued in the US.
NOTE: Prazepam is a schedule C-IV controlled substance.
Prazepam is an oral benzodiazepine used for the management of symptoms associated with anxiety disorders and for short-term amelioration of the symptoms of anxiety or anxiety associated with depression.
Shorter-duration benzodiazepines are often preferable to prazepam in the treatment of anxiety, particularly in the elderly or patients with liver disease, because prazepam produces an active metabolite with a prolonged half-life. Prazepam was approved by the FDA in 1976.
The Centrax® product was discontinued by the manufacturer in 1996; the FDA subsequently withdrew the NDA for this drug after market removal.
Indications
- anxiety
For the treatment of anxiety
Side Effects
- amnesia
- anxiety
- ataxia
- confusion
- depression
- dizziness
- drowsiness
- euphoria
- fatigue
- headache
- insomnia
- mania
- nightmares
- physiological dependence
- psychological dependence
- syncope
- teratogenesis
- tolerance
- tremor
- vertigo
- withdrawal
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- abrupt discontinuation
- benzodiazepine dependence
- benzodiazepine hypersensitivity
- breast-feeding
- children
- depression
- geriatric
- hepatic disease
- myasthenia gravis
- Parkinson’s disease
- porphyria
- pregnancy
- psychosis
- pulmonary disease
- renal failure
- renal impairment
- respiratory depression
- sleep apnea
- substance abuse
- suicidal ideation
Interactions
No information is available regarding drug interactions associated with Prazepam
